Table 3.
Maximum toxicity per patient during the overall treatment period (n = 6)
| Adverse event | NCI-CTC grade | |
|---|---|---|
| All grades, n (%) | ≥ Grade 3, n (%) | |
| Hematologic | ||
| Leukopenia | 5 (83) | 0 (0) |
| Neutropenia | 5 (83) | 0 (0) |
| Thrombocytopenia | 1 (17) | 0 (0) |
| Anemia | 2 (33) | 0 (0) |
| AST increased | 1 (17) | 0 (0) |
| ALT increased | 3 (50) | 1 (17) |
| Alkaline phosphatase increased | 2 (33) | 0 (0) |
| Hyperkalemia | 1 (17) | 0 (0) |
| Hypermagnesemia | 1 (17) | 1 (17) |
| Hypoalbuminemia | 3 (50) | 0 (0) |
| Hypocalcemia | 2 (33) | 1 (17) |
| Hypokalemia | 4 (67) | 2 (33) |
| Hyponatremia | 1 (17) | 1 (17) |
| Hypomagnesemia | 6 (100) | 1 (17) |
| Proteinuria | 1 (17) | 0 (0) |
| Non-hematologic | ||
| Abdominal pain | 1 (17) | 0 (0) |
| Alopecia | 4 (67) | – |
| Anorexia | 4 (67) | 0 (0) |
| Anal hemorrhage | 1 (17) | 0 (0) |
| Cheilitis | 1 (17) | 0 (0) |
| Conjunctivitis | 2 (33) | 0 (0) |
| Constipation | 3 (50) | 0 (0) |
| Diarrhea | 6 (100) | 3 (50) |
| Dry skin | 5 (83) | 0 (0) |
| Dysgeusia | 5 (83) | – |
| Fatigue | 2 (33) | 0 (0) |
| Febrile neutropenia | 0 (0) | 0 (0) |
| Fever | 1 (17) | 0 (0) |
| Hypertension | 1 (17) | 0 (0) |
| Infusion-related reaction | 3 (50) | 0 (0) |
| Malaise | 5 (83) | – |
| Nausea | 5 (83) | 0 (0) |
| Palpitations | 1 (17) | 0 (0) |
| Paronychia | 3 (50) | 0 (0) |
| Peripheral sensory neuropathy | 6 (100) | 0 (0) |
| Pruritus | 1 (17) | 0 (0) |
| Rash acneiform | 5 (83) | 0 (0) |
| Skin hyperpigmentation | 2 (33) | – |
| Stomatitis | 5 (83) | 2 (33) |
| Urticaria | 1 (17) | 0 (0) |
| Vomiting | 2 (33) | 0 (0) |
| Weight loss | 2 (33) | 0 (0) |